Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
复制标题
DOI：
10.1136/rmdopen-2017-000596
复制
发表时间：
2018
期刊：
影响因子：
6.2
通讯作者：
Hyrich KL
中科院分区：
文献类型：
--
作者：
Fagerli KM;Kearsley-Fleet L;Watson KD;Packham J;Contributors Group BR;Symmons DPM;Hyrich KL
肿瘤坏死因子α抑制剂（TNFi）的长期有效性主要在类风湿性关节炎（RA）患者中进行了探索，银屑病关节炎（PsA）患者的可用数据包括有限的随访。通过描述治疗持续性，研究首次TNFi在PsA人群中的长期有效性，确定与5年持续性相关的因素，并通过治疗持续性进一步研究后续TNFi治疗的比较长期有效性。纳入了经风湿病学家诊断为PsA的患者，这些患者接受了在英国风湿病学会生物制剂注册处（BSRBR）（2002-2006年）注册的首次TNFi。描述了不同时间点的治疗，并通过logistic回归确定了与5年治疗持续性相关的因素。Kaplan-Meier分析用于评估与第一次TNFi治疗和后续TNFi治疗的持续性相关的因素。5年时，46.7%的患者仍在接受初始TNFi治疗。更好的5年持续性与男性性别、使用依那西普或阿达木单抗而不是英夫利西单抗以及无基线合并症有关。第一次、第二次和第三次TNFi的五年持续性估计值（95% CI）分别为53%（49%至57%）、60%（43%至57%）和48%（36%至59%）。我们发现，对于第一次和随后的TNFi治疗，TNFi在该PsA人群中具有良好的长期持久性。持续性和相关临床因素之间的关系并不强，并证明了预测PsA中TNFi治疗结果的困难。
Long-term effectiveness of tumour necrosis factor alpha inhibitors (TNFi) has mainly been explored in patients with rheumatoid arthritis (RA) and the data available on patients with psoriatic arthritis (PsA) includes limited follow-up. Investigate long-term effectiveness of first TNFi in a PsA population by describing treatment persistence, identify factors associated with 5-year persistence and further investigate comparative long-term effectiveness of subsequent TNFi treatments through persistence to treatment. Patients with a rheumatologist diagnosis of PsA receiving their first TNFi registered in the British Society for Rheumatology Biologics Register (BSRBR) (2002–2006) were included. Treatment at different time points was described and factors associated with 5-year treatment persistence were identified by logistic regression. Kaplan-Meier analysis was used to assess factors associated with persistence to first TNFi and subsequent TNFi treatments. At 5 years, 46.7% of patients were still on their initial TNFi treatment. Better 5 -year persistence was associated with male gender, use of etanercept or adalimumab rather than infliximab and absence of baseline comorbidity. Five-year persistence estimates (95% CI) of first, second and third TNFi were 53% (49% to 57%), 60% (43% to 57%) and 48% (36% to 59%), respectively. We found good long-term persistence of TNFi in this PsA population both for the first and subsequent TNFi treatments. The relationship between persistence and relevant clinical factors was not strong and demonstrates the difficulties in predicting outcome of TNFi treatment in PsA.
登录
查看更多内容
影响因子：
5.5
作者：
Saad, Amr A.;Ashcroft, Darren M.;Hyrich, Kimme L.
通讯作者：
Hyrich, Kimme L.
影响因子：
--
作者：
Glintborg, Bente;Ostergaard, Mikkel;Hetland, Merete Lund
通讯作者：
Hetland, Merete Lund
影响因子：
27.4
作者：
Fransen, J.;Antoni, C.;Van Riel, P. L. C. M.
通讯作者：
Van Riel, P. L. C. M.
DOI：
10.1002/art.23333
发表时间：
2008-02-15
期刊：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子：
--
作者：
Heiberg, Marte Schrumpf;Koldingsnes, Wenche;Kvien, Tore K.
通讯作者：
Kvien, Tore K.
影响因子：
27.4
作者：
Fagerli, Karen Minde;Lie, Elisabeth;Kvien, Tore K.
通讯作者：
Kvien, Tore K.